Thermo Fisher Scientific

Wednesday, April 13, 2022 at 2pm EST | 1pm CST | 11am PST Selecting raw materials for developing and manufacturing is not a trivial decision. Join us and learn how to avoid mistakes in raw material selection that can delay or prevent a promising mRNA therapeutic or vaccine from reaching the market..

One of the harsher realities to balance in the biotechnology and life sciences industries is that success in the lab is not the same as success in business, and you have to run a successful business to keep the lab going. Kurt Gielen, co-founder and chief business officer of Medace, knew he didn’t belong in the lab but also that a career in the biotech business was his calling. Now he’s leveraging his 20 years of experience in the industry to help young companies strike that balance between business and science. Medace offers an innovative co-working environment where research and entrepreneurship meet – and grow. Kurt shares his path from the lab, across the globe, and eventually to this unique Belgium-based incubator committed to turning research into reality and discusses why he’s committed to making Medace’s resources and knowledge accessible to fledgling biotech companies all over the world.

A simple UHPLC-CAD platform was developed for confident and accurate characterization of identity, purity and ratio of lipid components in lipid nanoparticle (LNP) formulations.

When university and industry researchers work in tandem to conquer big challenges in medicine, they can achieve much more together than they ever could apart. Sue Fletcher, a pioneer in RNA therapeutic and Chief Scientific Officer at PYC Therapeutics, know this firsthand. She has spent decades in the field and is the co-developer of some revolutionary genetic therapies for treating rare diseases. Here, Dr. Fletcher speaks with BioPharm International about her work in this field, her incredible career, and how she’s inspiring young scientists in this complex area.

Cell and gene therapies may well be some of the most important recent advancements in modern medicine. The way they work, however, is very complex and completely different from any pill that simply addresses symptoms. So who are the pioneers in this field and what dares them to ask “what if”? In this episode of the Building Biotechs podcast series sponsored by Thermo Fisher Scientific, learn from Ainslie Little, senior vice president of corporate strategy at BlueRock Therapeutics, how her company’s cell & gene platform is breaking new ground in this important space.